DE60006618D1 - Tetrahydro-benzo(d)azepine und deren Verwendung als metabotrope Glutamatrezeptor-Antagonisten - Google Patents
Tetrahydro-benzo(d)azepine und deren Verwendung als metabotrope Glutamatrezeptor-AntagonistenInfo
- Publication number
- DE60006618D1 DE60006618D1 DE60006618T DE60006618T DE60006618D1 DE 60006618 D1 DE60006618 D1 DE 60006618D1 DE 60006618 T DE60006618 T DE 60006618T DE 60006618 T DE60006618 T DE 60006618T DE 60006618 D1 DE60006618 D1 DE 60006618D1
- Authority
- DE
- Germany
- Prior art keywords
- azepines
- tetrahydrobenzo
- receptor antagonists
- glutamate receptor
- metabotropic glutamate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Psychology (AREA)
- Diabetes (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Ophthalmology & Optometry (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Otolaryngology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP99115557 | 1999-08-06 | ||
EP99115557 | 1999-08-06 |
Publications (2)
Publication Number | Publication Date |
---|---|
DE60006618D1 true DE60006618D1 (de) | 2003-12-24 |
DE60006618T2 DE60006618T2 (de) | 2004-09-23 |
Family
ID=8238742
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60006618T Expired - Fee Related DE60006618T2 (de) | 1999-08-06 | 2000-07-27 | Tetrahydro-benzo(d)azepine und deren Verwendung als metabotrope Glutamatrezeptor-Antagonisten |
Country Status (27)
Country | Link |
---|---|
US (1) | US6218385B1 (de) |
JP (1) | JP3260350B2 (de) |
KR (1) | KR100390116B1 (de) |
CN (1) | CN1146455C (de) |
AR (1) | AR025035A1 (de) |
AT (1) | ATE254614T1 (de) |
AU (1) | AU774485B2 (de) |
BR (1) | BR0003375A (de) |
CA (1) | CA2314798A1 (de) |
CO (1) | CO5180625A1 (de) |
DE (1) | DE60006618T2 (de) |
ES (1) | ES2209728T3 (de) |
HR (1) | HRP20000520A2 (de) |
HU (1) | HUP0003112A3 (de) |
ID (1) | ID26743A (de) |
IL (1) | IL137688A0 (de) |
MA (1) | MA26748A1 (de) |
NO (1) | NO20003966L (de) |
NZ (1) | NZ506096A (de) |
PE (1) | PE20010467A1 (de) |
PL (1) | PL341890A1 (de) |
RU (1) | RU2240317C2 (de) |
SG (1) | SG93251A1 (de) |
TR (1) | TR200002298A3 (de) |
UY (1) | UY26276A1 (de) |
YU (1) | YU49700A (de) |
ZA (1) | ZA200003927B (de) |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2432077C (en) * | 2000-12-22 | 2011-01-18 | F. Hoffmann-La Roche Ag | Tetrahydro-(benzo or thieno)-azepine-pyrazine and triazine derivatives as mglur 1 antagonists |
US6953787B2 (en) | 2002-04-12 | 2005-10-11 | Arena Pharmaceuticals, Inc. | 5HT2C receptor modulators |
NZ540148A (en) * | 2002-12-20 | 2007-11-30 | Glaxo Group Ltd | Benzazepine derivatives for the treatment of neurological disorders |
EA016558B1 (ru) * | 2003-06-17 | 2012-05-30 | Арена Фармасьютикалз, Инк. | Производные бензазепина, используемые для лечения заболеваний, ассоциированных с 5-ht-рецептором |
HUE028976T2 (en) * | 2003-06-17 | 2017-02-28 | Arena Pharm Inc | 8-Chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride |
US20080009478A1 (en) * | 2003-10-22 | 2008-01-10 | Arena Pharmaceuticals, Inc. | Benzazepine Derivatives and Methods of Prophylaxis or Treatment of 5Ht2c Receptor Associated Diseases |
WO2005042490A1 (en) * | 2003-10-22 | 2005-05-12 | Arena Pharmaceuticals, Inc. | Benzazepine derivatives and methods of prophylaxis or treatment of 5ht2c receptor associated diseases |
JP5270167B2 (ja) | 2004-12-21 | 2013-08-21 | アリーナ ファーマシューティカルズ, インコーポレイテッド | (r)−8−クロロ−1−メチル−2,3,4,5−テトラヒドロ−1h−3−ベンザゼピン塩酸塩の結晶形 |
CN102631349A (zh) | 2004-12-23 | 2012-08-15 | 艾尼纳制药公司 | 5HT2c受体调节剂组合物和使用方法 |
JP2009506069A (ja) | 2005-08-26 | 2009-02-12 | ブレインセルス,インコーポレイティド | ムスカリン性受容体調節による神経発生 |
EP2258359A3 (de) | 2005-08-26 | 2011-04-06 | Braincells, Inc. | Neurogenese durch Modulation des Muscarinrezeptors mit Sabcomelin |
AU2006304787A1 (en) | 2005-10-21 | 2007-04-26 | Braincells, Inc. | Modulation of neurogenesis by PDE inhibition |
CA2625210A1 (en) | 2005-10-31 | 2007-05-10 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
JP5199997B2 (ja) | 2006-04-03 | 2013-05-15 | アリーナ ファーマシューティカルズ, インコーポレイテッド | 8−クロロ−1−メチル−2,3,4,5−テトラヒドロ−1h−3−ベンズアゼピンおよびこれに関連する中間体を調製するためのプロセス |
EP2026813A2 (de) | 2006-05-09 | 2009-02-25 | Braincells, Inc. | 5-ht-rezeptor-vermittelte neurogenese |
EP2377531A2 (de) | 2006-05-09 | 2011-10-19 | Braincells, Inc. | Neurogenese mittels Angiotensin-Modulation |
EP1873527A1 (de) * | 2006-06-30 | 2008-01-02 | Schwarz Pharma Ag | Verfahren zur Identifizierung von CRMP-Modulatoren |
US7998971B2 (en) | 2006-09-08 | 2011-08-16 | Braincells Inc. | Combinations containing a 4-acylaminopyridine derivative |
US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
CA2670116C (en) | 2006-11-22 | 2015-03-10 | Seaside Therapeutics, Llc | Methods of treating mental retardation, down's syndrome, fragile x syndrome and autism |
CN101547892B (zh) * | 2006-12-05 | 2014-08-20 | 艾尼纳制药公司 | 制备(r)-8-氯-1-甲基-2,3,4,5-四氢-1h-3-苯并氮杂卓的方法和其中间体 |
TW200845978A (en) * | 2007-03-07 | 2008-12-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives |
JP5491421B2 (ja) | 2008-03-04 | 2014-05-14 | アリーナ ファーマシューティカルズ, インコーポレイテッド | 5−ht2cアゴニストである(r)−8−クロロ−1−メチル−2,3,4,5−テトラヒドロ−1h−3−ベンゾアゼピンに関連する中間体の調製のためのプロセス |
US20100216805A1 (en) | 2009-02-25 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
WO2010148207A2 (en) | 2009-06-18 | 2010-12-23 | Arena Pharmaceuticals, Inc. | Processes for the preparation of 5-ht2c receptor agonists |
WO2011109398A2 (en) | 2010-03-02 | 2011-09-09 | President And Fellows Of Harvard College | Methods and compositions for treatment of angelman syndrome and autism spectrum disorders |
US20110294879A1 (en) | 2010-05-28 | 2011-12-01 | Xenoport, Inc. | Method of treatment of fragile x syndrome, down's syndrome, autism and related disorders |
WO2011153206A1 (en) | 2010-06-02 | 2011-12-08 | Arena Pharmaceuticals, Inc. | Processes for the preparation of 5-ht2c receptor agonists |
US20120016021A1 (en) | 2010-07-15 | 2012-01-19 | Xenoport, Inc. | Methods of treating fragile x syndrome, down's syndrome, autism and related disorders |
SG10201506870PA (en) | 2010-09-01 | 2015-10-29 | Arena Pharm Inc | Salts of lorcaserin with optically active acids |
SG188362A1 (en) | 2010-09-01 | 2013-04-30 | Arena Pharm Inc | Modified-release dosage forms of 5-ht2c agonists useful for weight management |
US8999970B2 (en) | 2010-09-01 | 2015-04-07 | Arena Pharmaceuticals, Inc. | Administration of an anti-obesity compound to individuals with renal impairment |
EP2611433A2 (de) | 2010-09-01 | 2013-07-10 | Arena Pharmaceuticals, Inc. | Nicht-hygroskopische salze aus 5-ht2c-agonisten |
KR20150070249A (ko) | 2012-10-09 | 2015-06-24 | 아레나 파마슈티칼스, 인크. | 체중 관리 방법 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4206210A (en) * | 1977-01-19 | 1980-06-03 | Smithkline Corporation | Alkylthio-7,8-dihdroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepines having dopaminergic activity |
DK0556310T3 (da) * | 1990-11-06 | 1995-08-21 | Pfizer | Quinazolinderivater til forhøjelse af antitumoraktivitet |
US5241065A (en) * | 1992-02-25 | 1993-08-31 | Schering Corporation | 2,3,4,5-tetrahydro-1h-3-benzazepines having anti-psychotic activity |
-
2000
- 2000-07-27 ES ES00116091T patent/ES2209728T3/es not_active Expired - Lifetime
- 2000-07-27 DE DE60006618T patent/DE60006618T2/de not_active Expired - Fee Related
- 2000-07-27 AT AT00116091T patent/ATE254614T1/de not_active IP Right Cessation
- 2000-08-01 US US09/630,702 patent/US6218385B1/en not_active Expired - Fee Related
- 2000-08-01 NZ NZ506096A patent/NZ506096A/xx unknown
- 2000-08-01 MA MA26033A patent/MA26748A1/fr unknown
- 2000-08-01 CA CA002314798A patent/CA2314798A1/en not_active Abandoned
- 2000-08-02 SG SG200004344A patent/SG93251A1/en unknown
- 2000-08-02 AU AU48979/00A patent/AU774485B2/en not_active Ceased
- 2000-08-02 PE PE2000000768A patent/PE20010467A1/es not_active Application Discontinuation
- 2000-08-02 ID IDP20000655A patent/ID26743A/id unknown
- 2000-08-02 HR HR20000520A patent/HRP20000520A2/hr not_active Application Discontinuation
- 2000-08-02 ZA ZA200003927A patent/ZA200003927B/xx unknown
- 2000-08-03 CO CO00058410A patent/CO5180625A1/es not_active Application Discontinuation
- 2000-08-03 IL IL13768800A patent/IL137688A0/xx unknown
- 2000-08-04 AR ARP000104022A patent/AR025035A1/es not_active Application Discontinuation
- 2000-08-04 NO NO20003966A patent/NO20003966L/no not_active Application Discontinuation
- 2000-08-04 UY UY26276A patent/UY26276A1/es not_active Application Discontinuation
- 2000-08-04 TR TR2000/02298A patent/TR200002298A3/tr unknown
- 2000-08-04 JP JP2000236848A patent/JP3260350B2/ja not_active Expired - Fee Related
- 2000-08-04 HU HU0003112A patent/HUP0003112A3/hu unknown
- 2000-08-04 RU RU2000120522/04A patent/RU2240317C2/ru not_active IP Right Cessation
- 2000-08-04 KR KR10-2000-0045324A patent/KR100390116B1/ko not_active IP Right Cessation
- 2000-08-04 CN CNB001225235A patent/CN1146455C/zh not_active Expired - Fee Related
- 2000-08-07 YU YU49700A patent/YU49700A/sh unknown
- 2000-08-07 PL PL00341890A patent/PL341890A1/xx unknown
- 2000-08-07 BR BR0003375-8A patent/BR0003375A/pt not_active Application Discontinuation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60006618D1 (de) | Tetrahydro-benzo(d)azepine und deren Verwendung als metabotrope Glutamatrezeptor-Antagonisten | |
DE60009116D1 (de) | Benzodiazepinderivate und deren verwendung als metabotrope glutamatrezeptor antagonisten | |
DE60005386D1 (de) | Benzodiazepinderivate und deren verwendung als metabotrope glutamatrezeptor antagonisten | |
DE60015296D1 (de) | Indolderivate und ihre verwendung als mcp-1 rezeptor antagonisten | |
DE60045564D1 (de) | 4-Phenylpyridinderivate und deren Verwendung als NK-1 Rezeptorantagonisten | |
HUP0301665A2 (en) | Novel benzazepines and related heterocyclic derivatives which are useful as orexin receptor antagonists | |
IL144270A0 (en) | Tricyclic benzodiazepines as vasopressin receptor antagonists | |
ATE280158T1 (de) | 3-phenylpyridinderivative und deren verwendung als nk-1 rezeptorantagonisten | |
EP1100506A4 (de) | Integrin rezeptor antagonisten | |
EP1105389A4 (de) | Integrinreceptorantagonisten | |
DE69925730D1 (de) | 4-benzyl-piperidin-alkylsulfoxid-heterozyklen und ihre verwendung als subtyp-selektive nmda rezeptor antagonisten | |
EP1254116A4 (de) | Alpha v integrin-rezeptor antagonisten | |
DE60106607D1 (de) | Substituierte 1-aminoalkyl-lactame und ihre verwendung als muscarinrezeptor antagonisten | |
DE60114413D1 (de) | Substituierte 1-aminoalkyl-lactame und deren verwendung als muscarinrezeptor-antagonisten | |
EP1229910A4 (de) | Integrinrezeptorantagonisten | |
EP1252162A4 (de) | Alpha v integrin rezeptor antagonisten | |
EP1194151A4 (de) | Antagonisten der integrin rezeptoren | |
EP1150965A4 (de) | Benzazepin derivate als alpha-v intgrin rezeptor antagonisten | |
EP1248607A4 (de) | Urotensin-ii rezeptorantagonisten | |
AU9259801A (en) | Alpha v integrin receptor antagonists | |
IL148043A0 (en) | Novel integrin receptor antagonists | |
ATE353881T1 (de) | 1,4-diazepan-2,5-dion-derivate und deren verwendung als nk-1 rezeptorantagonisten | |
IL146146A0 (en) | Integrin receptor antagonists | |
GB9820014D0 (en) | Receptor antagonists and uses thereof | |
EP1169042A4 (de) | Dibenzoazepinderivate als alpha-v integrin rezeptor antagonisten |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition | ||
8339 | Ceased/non-payment of the annual fee |